von Hippel-Lindau 与缺氧诱导因子在肾细胞癌生物学中的核心地位。
von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
机构信息
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Brigham and Women's Hospital, Harvard Medical School; Howard Hughes Medical Institute.
出版信息
Hematol Oncol Clin North Am. 2023 Oct;37(5):809-825. doi: 10.1016/j.hoc.2023.04.011. Epub 2023 Jun 1.
Abstract
The most common form of kidney cancer is clear cell renal cell carcinoma (ccRCC). Biallelic VHL tumor suppressor gene inactivation is the usual initiating event in both hereditary (VHL Disease) and sporadic ccRCCs. The VHL protein, pVHL, earmarks the alpha subunits of the HIF transcription factor for destruction in an oxygen-dependent manner. Deregulation of HIF2 drives ccRCC pathogenesis. Drugs inhibiting the HIF2-responsive growth factor VEGF are now mainstays of ccRCC treatment. A first-in-class allosteric HIF2 inhibitor was recently approved for treating VHL Disease-associated neoplasms and appears active against sporadic ccRCC in early clinical trials.
摘要
最常见的肾癌类型是肾透明细胞癌（ccRCC）。VHL 抑癌基因的双等位基因失活是遗传性（VHL 病）和散发性 ccRCC 的常见起始事件。VHL 蛋白 pVHL 以氧依赖的方式标记 HIF 转录因子的α亚基进行降解。HIF2 的失调驱动 ccRCC 的发病机制。抑制 HIF2 反应性生长因子 VEGF 的药物现已成为 ccRCC 治疗的主要方法。最近批准了一种新型的别构 HIF2 抑制剂用于治疗 VHL 病相关肿瘤，并在早期临床试验中对散发性 ccRCC 表现出活性。
相似文献
1
von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.von Hippel-Lindau 与缺氧诱导因子在肾细胞癌生物学中的核心地位。
Hematol Oncol Clin North Am. 2023 Oct;37(5):809-825. doi: 10.1016/j.hoc.2023.04.011. Epub 2023 Jun 1.
2
Sensitivity of mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.突变型肾癌对 HIF2 抑制剂的敏感性并不需要完整的 p53 通路。
Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119. doi: 10.1073/pnas.2120403119. Epub 2022 Mar 31.
3
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.缺氧、缺氧诱导转录因子与肾癌
Eur Urol. 2016 Apr;69(4):646-657. doi: 10.1016/j.eururo.2015.08.007. Epub 2015 Aug 19.
4
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.肾透明细胞癌程序性死亡配体 1 是缺氧诱导因子-2α的新的直接靶标，受 von Hippel-Lindau 基因突变状态调控。
Eur Urol. 2016 Oct;70(4):623-632. doi: 10.1016/j.eururo.2015.11.029. Epub 2015 Dec 23.
5
Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.结节性硬化症复合物蛋白1的表达受散发性透明细胞肾细胞癌中VHL基因改变和HIF-1α产生的影响。
Exp Mol Pathol. 2016 Dec;101(3):323-331. doi: 10.1016/j.yexmp.2016.11.003. Epub 2016 Nov 12.
6
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.硒通过脯氨酰羟化酶 2 依赖性和 von Hippel-Lindau 非依赖性降解，抑制肾透明细胞癌细胞中低氧诱导因子 1 和 2α，从而抑制肿瘤生长。
BMC Cancer. 2012 Jul 17;12:293. doi: 10.1186/1471-2407-12-293.
7
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.von Hippel-Lindau 肿瘤抑制蛋白通过组蛋白去甲基酶 JARID1C 调节基因表达和肿瘤生长。
Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.
8
Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.贝伐单抗、HIF-2α 抑制剂与伴有体细胞 Von-Hippel-Lindau 功能丧失突变的透明细胞肾细胞癌。
J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241231641. doi: 10.1177/23247096241231641.
9
Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.低级别和高级别散发性透明细胞肾细胞癌中不同的血管生成潜能与冯·希佩尔-林道基因的改变无关。
Cell Oncol. 2009;31(5):371-82. doi: 10.3233/CLO-2009-0482.
引用本文的文献
1
Radiogenomics of Stereotactic Radiotherapy: Genetic Mechanisms Underlying Radiosensitivity, Resistance, and Immune Response.立体定向放射治疗的放射基因组学：放射敏感性、抗性和免疫反应背后的遗传机制。
Genes (Basel). 2025 Jun 24;16(7):732. doi: 10.3390/genes16070732.
2
Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer.细胞周期蛋白D1的需求是肾癌中细胞自主HIF2依赖性的基础。
Cancer Discov. 2025 Jul 3;15(7):1484-1504. doi: 10.1158/2159-8290.CD-24-1378.
3
Translocation renal cell carcinoma says no to the Warburg effect.易位性肾细胞癌对瓦伯格效应说“不”。
Nat Metab. 2025 Mar;7(3):438-440. doi: 10.1038/s42255-025-01216-x.
4
HIF1α Plays a Crucial Role in the Development of TFE3-Rearranged Renal Cell Carcinoma by Orchestrating a Metabolic Shift Toward Fatty Acid Synthesis.缺氧诱导因子1α通过调控向脂肪酸合成的代谢转变，在TFE3重排肾细胞癌的发展中起关键作用。
Genes Cells. 2025 Jan;30(1):e13195. doi: 10.1111/gtc.13195.
5
Advancements in understanding the molecular mechanisms and clinical implications of Von Hippel-Lindau syndrome: A comprehensive review.冯·希佩尔-林道综合征分子机制及临床意义的研究进展：综述
Transl Oncol. 2025 Jan;51:102193. doi: 10.1016/j.tranon.2024.102193. Epub 2024 Nov 21.
6
A framework for target discovery in rare cancers.罕见癌症中靶点发现的框架。
bioRxiv. 2024 Nov 20:2024.10.24.620074. doi: 10.1101/2024.10.24.620074.
7
VHL governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas.VHL调控透明细胞肾细胞癌中的m6A修饰和PIK3R3 mRNA稳定性。
J Clin Invest. 2024 Apr 15;134(8):e179560. doi: 10.1172/JCI179560.
8
Improved therapy for clear cell renal cell carcinoma: beta-hydroxybutyrate and quercetin target hypoxia-induced angiogenesis and multidrug resistance.改善透明细胞肾细胞癌的治疗方法：β-羟基丁酸和槲皮素靶向缺氧诱导的血管生成和多药耐药。
Mol Biol Rep. 2024 Mar 2;51(1):379. doi: 10.1007/s11033-024-09355-2.
本文引用的文献
1
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.缺氧诱导因子 2 阿尔法（HIF2α）抑制剂：针对遗传驱动的肿瘤缺氧。
Endocr Rev. 2023 Mar 4;44(2):312-322. doi: 10.1210/endrev/bnac025.
2
HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.在小鼠和人体内使用靶向肿瘤的 RNA 干扰药物抑制 HIF2 及其肿瘤抑制作用。
Clin Cancer Res. 2022 Dec 15;28(24):5405-5418. doi: 10.1158/1078-0432.CCR-22-0963.
3
Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer.希佩尔-林道病：氧感应、蛋白降解和癌症的研究进展。
J Clin Invest. 2022 Sep 15;132(18):e162480. doi: 10.1172/JCI162480.
4
Sensitivity of mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.突变型肾癌对 HIF2 抑制剂的敏感性并不需要完整的 p53 通路。
Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119. doi: 10.1073/pnas.2120403119. Epub 2022 Mar 31.
5
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
6
PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner.PBRM1 失活以依赖 HIF 的方式促进人类内源性逆转录病毒的上调。
Cancer Immunol Res. 2022 Mar 1;10(3):285-290. doi: 10.1158/2326-6066.CIR-21-0480.
7
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.贝伐珠单抗治疗 von Hippel-Lindau 病相关肾细胞癌
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
8
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.MK-6482作为治疗与希佩尔-林道病相关的透明细胞肾细胞癌的潜在疗法。
Expert Opin Investig Drugs. 2021 May;30(5):495-504. doi: 10.1080/13543784.2021.1925248. Epub 2021 May 20.
9
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.用贝佐蒂凡抑制肾细胞癌中的缺氧诱导因子-2α：一项1期试验及生物标志物分析
Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22.
10
Multi-omics analysis reveals contextual tumor suppressive and oncogenic gene modules within the acute hypoxic response.多组学分析揭示了急性低氧反应中与肿瘤抑制和致癌相关的基因模块的上下文依赖性。
Nat Commun. 2021 Mar 2;12(1):1375. doi: 10.1038/s41467-021-21687-2.
Zotero 插件